In a report released on March 28, Yang Huang from J.P. Morgan maintained a Buy rating on Innovent Biologics (IVBXF – Research Report), with a ...
SAN FRANCISCO and SUZHOU, China, March 30, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that ...
Vietnam Investment Review on MSN10d
Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 for Platinum-resistant Ovarian CancerInnovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high quality ...
(RTTNews) - Innovent Biologics Inc. (IVBXF.OB) announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has granted Breakthrough Therapy ...
Innovent Biologics begins patient dosing in phase 3 study of IBI354 for platinum-resistant ovarian cancer: San Francisco Tuesday, March 25, 2025, 18:00 Hrs [IST] Innovent Biologic ...
First-ever positive profit, entering a new era of growth and global innovation SAN FRANSISCO and SUZHOU, China, March 26, 2025 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: ...
PR Newswire SAN FRANCISCO and SUZHOU, China, March 30, 2025 SAN FRANCISCO and SUZHOU, China, March 30, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a ...
SAN FRANSISCO and SUZHOU, China, March 26, 2025 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and ...
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, ...
China NMPA grants breakthrough therapy designation for Innovent’s PD-1/IL-2a-bias bispecific antibody fusion protein, IBI363 in melanoma: San Francisco, US Tuesday, April 1, 202 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback